Introduction
Although antivascular therapies have been useful in shrinking tumors and in increasing the time to progression (Fox et al., 2007; Samant and Shevde, 2011) , to date, very few of these drugs have been effective in promoting long term survival (Fox et al., 2007) .
Redundancy in pathways and growth factors that support the formation of tumor neo-vasculature contribute to rapid vascular regrowth in tumors after discontinuation of antiangiogenic treatment (Mancuso et al., 2006) . Thus, there is a need for alternate targets and strategies to treat tumor vasculature to combat intrinsic resistance and acquired resistance to antiangiogenic drugs.
The hedgehog (Hh) pathway is activated in several cancers (Merchant and Matsui, 2010; Yang et al., 2010) . Canonical Hh pathway activation ensues the binding of ligands, SHH/IHH/DHH, to the extracellular domain of the membrane-bound receptor Patched (Beachy et al., 2010) . This causes a release of inhibitory actions of Patched on Smoothed (reviewed by Cohen, 2010) , which results in the activation of the GLI family of transcription factors. The Hh pathway has been studied for its involvement in angiogenesis and vasculogenesis during ontogeny (Hochman et al., 2006) . In cancer, aberrant upregulation of Hh signaling impacts the tumor microenvironment and contributes to tumor progression (Bailey et al., 2009; Zunich et al., 2009; Cao et al., 2011; O'Toole et al., 2011) .
In this study we report the identification of a novel, VEGF-independent, clinically relevant, transcriptional target of Hh-GLI signaling, CYR61 (cysteine rich angiogenic inducer 61). We have investigated the impact of autocrine/homotypic Hh signaling on tumor cells and have also characterized paracrine Hh signaling involving tumor cells and endothelial cells. Hh signaling mediated upregulation of CYR61 in breast cancer cells causes an increase in the tumor vasculature and supports an environment for metastasis. Thus, strategies targeting the Hh signaling could potentially form an effective approach for intervening in tumor vascularization.
Results

Expression of SHH in breast cancer cells enhances their malignant attributes
In order to assess the role of Hh signaling in breast tumor vascularity and metastasis, we engineered breast cancer cell lines with endogenously low expression of the prominent Hh pathway-activating molecule, SHH, to constitutively express this ligand. Human breast cancer cells, MDA-MB-231 and MCF10AT, were selected not only for their relatively low expression of SHH but also because of the fact that both cell lines are incapable of spontaneous metastasis in xenograft models of breast cancer (Zhang et al., 1991; Santner et al., 2001) . We detected the 19 kDa fragment, which is classically secreted and is the biologically active fragment in conditioned media (CM) (Porter et al., 1995) (Figure 1a, Supplementary Figure 1A) .
Expression of SHH caused activation of Hh signaling in the cells as indicated by the increase in GLI reporter activity in SHH-expressing cells compared with the vector-control group (Po0.0001) (Supplementary Figure 1B) as well as an increase in the transcript levels of Patched, also a GLI-target gene (data not shown) (Mukherjee et al., 2006; Lu et al., 2008) . We assessed the impact of constitutive Hh signaling on attributes of malignancy including cell proliferation, anchorage and contact independent growth, motility and invasion. SHH-expressing cells displayed significantly rapid proliferation (Po0.0001) with an average doubling time of 27 h compared with vector-control cells (32 h) ( Figure 1b ). SHH expression also significantly enhanced the ability for contact-independent growth (foci formation assay; P ¼ 0.03) and anchorage-independent growth (soft agar assay; Po0.0001) (Figures 1c and d) . SHHexpressing cells displayed significantly enhanced motility (Po0.0001) ( Figure 1e ) and invasion through basement membrane (Po0.0001) ( Figure 1f ). Similar to the MDA-MB-231-SHH-expressing cells, the MCF10AT-SHH-expressing transfectants also exhibited significantly increased ability to grow in soft agar and were more motile compared with the vector-transfectants (Po0.0001) ( Supplementary Figures 1C and D) .
In vivo, SHH-expressing MDA-MB-231 cells showed increased tumor-take rate/incidence (Figure 2a ). Notably, we used only one-fifth the numbers of cells that are usually used in orthotopic injections in order to assess the impact of constitutive Hh signaling on the tumorigenicity of cells (Shevde et al., 2006) . Within 10 days of injection, all the SHH-expressing breast cancer cells had established palpable tumors in contrast to the vectorcontrol cells that showed a notable lag in tumor-take rate (Figure 2b ). SHH-expressing breast cancer cell lines also displayed exponential growth compared with the vector-control groups (Po0.0001) ( Figure 2b ). This may be likely because of the rapid proliferative rates of SHH-expressing cells. The tumors developed from SHH-expressing cells showed prominent, complex blood vessel formation, which were larger than the tumors of the vector-control group (Figure 2c ). Immunohistochemically, the SHH-expressing tumors showed a greater staining intensity (immunoreactive scores) for SHH (Po0.0001) and significantly greater numbers of proliferating cells as seen by the higher Ki67 labeling index (Po0.01) and enhanced vascularization (Po0.005) as evidenced by the increased (doubled relative to control) blood vessel density evident upon staining for Griffonia Simplicifolia Lectin I (Figures 2d and e ). Ten weeks post tumor removal the lungs were assessed for evidence of pulmonary metastasis. Notably, 100% of the mice injected with SHH-expressing MDA-MB-231 cells showed pulmonary metastases ( Figure 2f ). We were also able to recover viable EGFP-expressing tumor cells from the lungs (Figure 2g ). These cells expressed SHH at levels that were comparable with the injected cells (data not shown). In the light of the fact that the MDA-MB-231 cells cannot spontaneously metastasize, our data are exciting and implicate a role for Hh signaling in imparting metastatic potential upon tumor cells, likely due to enhancing the malignant potential of the tumor cells per se and also by increasing vascularity of the tumor.
Factors secreted by breast cancer cells with constitutive
Hh signaling promote pro-angiogenic behavior of endothelial cells in vitro Increased tumor vascularity suggested a crosstalk between tumor cells and endothelial cells. In order to determine the impact of constitutive Hh signaling in the breast cancer cells on their ability to influence endothelial cells, we assessed the response of endothelial cells to CM from the SHH-expressing breast cancer cells specifically with regard to migration, ability to invade extracellular matrices and form networks. As depicted in Figures 3a and b , CM from SHH-expressing MDA-MB-231 cells significantly enhanced the ability of endothelial cells of chemotactic migration (Po0.005) and degradation/invasion extracellular matrix proteins (Po0.02). The endothelial cells were also able to efficiently form networks (Po0.0001) (Figure 3c , Supplementary Figure 1E ) in the presence of CM from the SHHexpressing cells. The CM from the SHH-expressing cells was more potent (Po0.01) in inducing network formations relative to VEGF, which was used as a positive control. Notably, recombinant SHH was not as efficient at influencing invasive behavior of endothelial cells (f) Tumors from SHH expressing cells also yielded a high incidence of pulmonary metastasis. Shown are representative photomicrographs of the lung images using the Stereoscopic Zoom Microscope (Nikon SMZ1500, Nikon Instruments Inc.) denoting visible light (left panels) and UV fluorescence (right panels) imaging that allows visualization of EGFP-expressing metastatic cells. (g) The EGFP-expressing metastatic cells from the lungs were isolated in culture. Shown are representative photomicrographs in DIC and UV fluorescence.
Hedgehog pathway upregulates CYR61
LG Harris et al (Po0.005) and only a high concentration of SHH (50 nM) was as potent as the conditioned medium in enhancing migration of the endothelial cells (Figure 3a , Supplementary Figure 2A ), implying that additional components in the conditioned medium of the SHHexpressing breast cancer cells may influence endothelial cell behavior.
CYR61 is differentially expressed as a consequence of Hh signaling
In order to identify candidate targets generated by Hh signaling in breast cancer, which may contribute to potentiating endothelial cell behavior and vascularization of the tumor xenograft, we used mass spectrometry to analyze and compare the secretomes of SHH-expressing and vector-control groups. SHH protein was not detected amongst 4250 proteins detected from the secretome of the vector-control cells. In contrast, SHH was the thirty-third most abundant protein (based on Mascot scores) in the secretome from the SHH-expressing MDA-MB-231 cells. Corresponding to this change, we noted that CYR61 had a concomitant increase in abundance with a mascot score of over double that in the vector-transfectant cells. The same increase in abundance was also apparent using spectral counting where the vector-transfectant cells showed only 9 peptide hits, whereas the SHH-expressing MDA-MB-231 cells had 20 hits for CYR61. In concordance with this data, the SHH-expressing cells show upregulated levels of CYR61, at the transcript levels, as well as in the secretome (immunoblot analysis) (Figure 4a, Supplementary Figure 2B ). The xenografts from MDA-MB-231 cells expressing SHH also showed intense staining of CYR61 (Supplementary Figure 2C ). As activated Hh signaling culminates in the nuclear translocation of the GLI transcription factors, we speculated that CYR61 might be a GLI1 target gene. Our search revealed a putative GLI1-binding site within B1 kb upstream of the CYR61 transcription start site ( Figure 4b) . The CYR61 promoter is activated (Po0.0001) in SHH-expressing cell lines (Figure 4c , Supplementary Figure 2D ). Moreover, mutation or deletion of the GLI1 binding site in the CYR61 promoter significantly abrogated the activity of the CYR61 promoter in the presence of GLI1 (Figure 4d , Supplementary Figure 2E ). To further validate the functionality of the GLI1-CYR61 promoter binding relationship, we performed a chromatin immunoprecipitation analysis. We found that GLI1 binds the CYR61 promoter region as evidenced by a PCR product using GLI1-specific primers. Moreover, the SHH-expressing cell lines yielded a more robust PCR product upon amplification of the immunoprecipitated DNA further confirming that GLI1 transcriptionally enhances CYR61 (Figure 4e ).
Hh signaling mediated CYR61 expression contributes to enhanced breast cancer malignancy CYR61 promotes cell migration, chemotaxis and growth factor-induced DNA synthesis (Kleer et al., 2007; Feng et al., 2008; Sun et al., 2008) and is reported to be pro-angiogenic (Chen et al., 2001; Lin et al., 2005) . In order to determine the specific role of CYR61 downstream Hh signaling, we silenced the expression of CYR61 in SHH-expressing MDA-MB-231 cells using shRNA (Figure 5a ). This resulted in decreased invasion (Po0.0001) of the tumor cells ( Figure 5b ) and compromised their ability to induce endothelial cell network formation (Po0.0001) ( Figure 5c ). Although there was no change in the rate of proliferation in vitro (data not shown), in vivo, CYR61 knockdown resulted in a decrease in tumor growth rates (P ¼ 0.01) ( Figure 5d ) that was characterized by tumors that were notably less vascularized with fewer Ki67-positive cells/nuclei relative to the scrambled control-transfected SHH-expressing tumors (Figure 5e ). Also, the SHHexpressing CYR61-silenced xenografts from the MDA-MB-231 cells showed lower immunoreactive scores for CYR61, microvessel density (Po0.001) and a lower Ki67 labeling index (Po0.01), supporting our finding that silencing CYR61 results in slower-growing tumors, despite continued Hh signaling because of SHH expression ( Figure 5f ). The expression of SHH was comparable between the 'Scrambled' control and cells silenced stably for CYR61. The xenografts developed from cells silenced for CYR61 were also significantly less efficient in colonizing the lungs (P ¼ 0.01) (Figure 5g ).
SHH and CYR61 expression are concomitantly elevated in advanced breast cancer
We assessed clinical relevance of our findings by querying the expression of transcripts encoding SHH and CYR61 in normal breast tissue as well as breast tumor tissue. The expression of SHH and CYR61 are concomitantly greater in tissues representing advanced confirms that GLI1 binds to the promoter of CYR61. Input: total native chromatin isolated from cancer cells (indicated, vectortransfected or SHH-expressing); ChIP: PCR amplified DNA product is generated after immunoprecipitation with GLI1 antibody; Water: PCR water-control used to assess quality and lack of contamination; IgG: isotype control; Àve and þ ve control denote kit-provided negative and positive control primers, respectively; GLI1-specific primers were used to amplify the putative GLI1 binding site in CYR61 promoter region and non-specific primers were used as a control to amplify a region 1 KB downstream of the putative GLI1 binding in CYR61 promoter that is void of the GLI1 consensus sequence. (e) COS7 cells were transfected with CYR61 promoter and empty vector or GLI1-expressing construct. Although the wild-type CYR61 promoter bearing the GLI-binding site is significantly upregulated (eight-fold;^Po0.0001), mutation or deletion of the GLI binding site in the CYR61 promoter results in abrogation (^^Po0.005) of luciferase reporter activity of the CYR61 promoter indicating that GLI1 transcriptionally regulates CYR61 gene expression.
stage breast cancer (Po0.01) patients (Figures 6a and b ) demonstrating the colinear expression between SHH and CYR61 and their amplified transcript levels in advanced breast cancer. Notably, the transcript levels of SHH are smaller relative to those of CYR61; smaller changes in the levels of the SHH ligand correlate with transcript levels of a larger magnitude for a transcriptional target such as CYR61.
Discussion
The Hh pathway is activated in several types of cancers and has been implicated in contributing to tumor growth, progression and metastasis (Bailey et al., 2009; Das et al., 2009 Das et al., , 2011 Yang et al., 2010; Mazumdar et al., 2011) . Angiogenesis is a critical component of tumor metastasis. The vascular density of a tumor has been correlated with metastasis and with patient outcome and can function as an independent prognostic variable in breast cancer (Weidner et al., 1991) (reviewed in Zetter, 1998) . Our current work has defined a role for Hh signaling in functionally regulating breast cancer malignancy and vascularization. Furthermore, we have identified a novel target of GLI-Hh signaling, CYR61, which appears to be a contributing factor to the enhanced angiogenic and metastatic potential associated with Hh activation in breast cancer. Hh signaling has been well characterized for its role in embryonic angiogenesis (Pola et al., 2001; Byrd and Grabel, 2004; Vokes et al., 2004) (reviewed in Bicknell and Harris, 2004) and in adults during wound healing and in the repair of ischemia (Pola et al., 2001) . In tumors, SHH induces the expression of angiopoietins I and II and the family of VEGF-A, B and C from mesenchymal cells, highlighting the significance of Hh signaling in tumor associated fibroblasts to mediate tumor blood vessel formation (Kanda et al., 2003) . Although much of the antiangiogenic research has focused on VEGF, the success of antiangiogenic treatment is limited by low efficacy, mainly due to inadequate alternate targets and strategies that can eliminate resistant cells during treatment-induced tumor regression and due to paucity of selective drugs (Blagosklonny, 2004) . The survival of resistant cells is favored by the fact that there is redundancy in the pathways and growth factors that support formation of tumor neo-vasculature. The possible synergistic effects of these growth factors could contribute to rapid vascular regrowth in tumors after discontinuation of antiangiogenic treatment (Mancuso et al., 2006) . The angiogenic program requires the degradation of the basement membrane, endothelial cell migration, invasion of the extracellular matrix with endothelial cell proliferation and capillary lumen formation before maturation and stabilization of the new vasculature. Our research shows that breast cancer cells with constitutive Hh signaling can enhance the pro-angiogenic behavior of endothelial cells causing the tumor to be vascularized with dichotomous, large-diameter blood vessels. Our observations support previous reports of SHH enhanced vascularization following ischemia (Pola et al., 2001) .
Importantly, whereas secretome analysis did not reveal VEGF among the top 500 proteins, CYR61 was differentially upregulated in the SHH-expressing cells. CYR61 expression, like several of the key molecules in the Hh pathway, is upregulated in clinical evaluation of transformed tissues (Xie et al., 2001b (Xie et al., , 2004 Zhou et al., 2009) . Furthermore, there appears to be a correlation between the stage of cancer and CYR61 expression in that more advanced cancers often display increased expression of CYR61 (Xie et al., 2001a (Xie et al., , 2001b Tsai et al., 2002) . CYR61 has been shown to have a role in decreasing sensitivity to chemotherapeutic drugs such as paclitaxel (Lai et al., 2011) . Conversely, Dobroff and colleagues have reported that CYR61 is a tumor suppressor in melanoma (Dobroff et al., 2009) . As CYR61 and several of the other targets and molecules associated with Hh signaling are secreted, it is important to consider the overall tumor microenvironment, which is often unique for different types of cancers and is specific to individual patients. These differences may dictate the mechanisms of action as well as the overall effects of these molecules. We reported that in melanoma, Hh signaling upregulates osteopontin, which contributes to increased malignancy of melanoma (Das et al., 2009) . Perhaps in some contexts and in very specific niches, Hh signaling selectively modulates the tumor microenvironment. Also, both osteopontin and CYR61 function through the binding of integrins and heparin sulfate proteoglycans (Chen and Lau, 2009 ). Thus the distribution, expression and availability of signaling molecules' receptors may need to be considered in each type of cancer.
O'Toole and others have recently reported an association of Hh signaling with stromal components in breast cancer (O'Toole et al., 2011) . In our study, the upregulation of CYR61 as a downstream event of Hh signaling allowed the tumor to be richly vascularized and created permissive conditions for hematogenous metastasis. Further evidence from our lab indicates that the expression of CYR61 is reduced when the expression of GLI1 is abrogated from tumor cells (ongoing work; unpublished data). It remains unclear as to whether Hh ligands can activate canonical Hh signaling in endothelial cells. However, a growing body of research confirms that Hh ligands can induce pro-angiogenic endothelial behavior such as migration and network formation (Chinchilla et al., 2010; Renault et al., 2010) . It is a wellaccepted fact though that CYR61 directly induces endothelial cell migration, network formation and tissue remodeling associated with angiogenesis (Babic et al., 1998; Leu et al., 2002) . In the present study, we have elucidated the impact of autocrine as well as paracrine Hh signaling on tumor cells as well as endothelial cells, respectively. Such signaling fortifies the tumor microenvironment and supports cross talk between cell types. Taken together, our data suggests that Hh ligands (SHH) may synergize with CYR61 produced by breast cancer cells to induce robust tumor vascularization in vivo. As the concomitant deregulated expression of these molecules supports increased tumor vasculature, it Figure 6 The expression of SHH and CYR61 are increased in advanced breast tumors. We assessed the transcript levels of SHH and CYR61 in a panel of tissues encompassing normal breast tissue (n ¼ 4) and breast tumor tissues by quantitative real-time polymerase chain reaction. The panel included tissues representing stage 1 (n ¼ 2), stage 2 (n ¼ 24) and stages 3 and 4 (n ¼ 21). (a) Overall, the transcript levels of SHH are elevated in breast tumors derived from advanced stage breast cancer (^P ¼ 0.0027). (b) The transcript levels of CYR61 are significantly higher in advanced stage breast cancer relative to normal tissues (^P ¼ 0.0011). The data is represented as relative transcript levels of SHH and CYR61 normalized to b-actin.
can be speculated that in a clinical context, upregulated expression of SHH and CYR61 in the primary tumor may suggest an increased likelihood of metastasis and thus provide preemptive opportunities for therapeutic intervention.
In sum, we have defined a novel, VEGF-independent, clinically relevant, transcriptional target of Hh signaling, CYR61, that enhances tumor vascularization and promotes spontaneous hematogenous metastasis of breast tumor cells. As such, paracrine Hh signaling and CYR61 present attractive targets to design alternative strategies and mitigate resistance to conventional antiangiogenic therapy.
Materials and methods
Cell lines and cell culture MDA-MB-231 and COS7 cells were cultured in Dulbeco's Modified Eagle Medium/F12 (Invitrogen, Carlsbad, CA, USA) supplemented with fetal bovine serum (Atlanta Biologicals, Atlanta, GA, USA), sodium pyruvate (Invitrogen) and non-essential amino acids (Invitrogen). MCF10AT cells were cultured in DMEM/F12 (Invitrogen) supplemented with horse serum (ATCC, Manassas, VA, USA), insulin (Sigma-Aldrich, St Louis, MO, USA), epidermal growth factor (Sigma-Aldrich), cholera toxin (Sigma-Aldrich) and hydrocortisone (Sigma-Aldrich). Cells were grown at 37 1C in a humidified 5% CO 2 incubator. MDA-MB-231 cells were transfected with pIRES2-SHH-EGFP (gifted by Dr Wade Bushman, University of Wisconsin, Madison, WI, USA) and selected in medium supplemented with 500 mg/ml geneticin (Invitrogen). MCF10AT cells stably expressing SHH were generated by transfecting pIRES3-SHH-EGFP and selected in medium supplemented with 250 ng/ml puromycin (Invitrogen). MDA-MB-231 cells stably silenced for CYR61 using shRNA cloned into pSUPER were selected in medium supplemented with 500 mg/ml geneticin and 300 mg/ml puromycin. All experiments were performed within no greater than 10 passages from each other in order to ensure genotypic and phenotypic fidelity between experiments.
CM was harvested from 1 Â 10 6 cells after 18 h, cleared by centrifugation at 800 rpms for 8 min and used in assays described below.
Quantitative real-time polymerase chain reaction cDNA was synthesized from total RNA (1 mg) using the High Capacity Reverse Transcriptase Kit (Applied Biosystems, Foster City, CA, USA) using the following conditions: 25 1C for 10 min, 37 1C for 120 min and 85 1C for 5 s. Expression of SHH and CYR61 was assessed using primer probes (Applied Bioystems) in the BioRad iQ5 Real-Time Detection System (Bio-Rad, Hercules, CA, USA) using the Applied Biosystem 2-Step PCR program. GAPDH or b-actin served as endorse control genes. Amplified gene transcripts were normalized to the endorse control genes (CT gene ÀCT control ¼ DCT). The fold changes observed in the experimental groups were expressed as ratios of experimental (2 À(DDct) )/control (2 À(DDct) ). Each experiment was performed in triplicate and repeated at least once.
SHH and CYR61 mRNA expression in human breast cancer patient tissues was analyzed using tissue qPCR array cDNA samples from OriGene Technologies (Rockville, MD, USA). qPCR was performed per the manufacturers' recommendations. Fold changes in expression were calculated relative to endorse control, b-actin (Trimmer et al., 2010; Gulhati et al., 2011) .
Western blot analysis
Lysates of cells were harvested in NP-40 buffer and quantitated spectrophotomically. Equal amounts of protein were determined and resolved by SDS-PAGE. Proteins were immunoblotted for SHH (N-19; Santa Cruz, Santa Cruz, CA, USA), Cyr61 (H-78; Santa Cruz), GAPDH (Cell Signaling, Beverly, MA, USA), or a/b tubulin (Cell Signaling) blots were developed using Super-Signal (Pierce, Rockford, IL, USA) and imaged on a Fuji LAS3000 imager (GE Healthcare, Fairfield, CT, USA).
Mass spectrometry analysis
Secreted proteomes were isolated and analyzed as described previously (Mbeunkui et al., 2007) . Details are as follows: serum free media was added to a 100 mm tissue culture plate seeded with 8 Â 10 5 cells. After 16 h, the serum free, conditioned media was acidified with 10% trifluoroacetic acid to promote protein stabilization. Proteins were isolated and fractioned from media using a tC2 reverse phase column and eluted using increasing concentrations of acetonitrile. Eluted proteins were dried and trypsin digested overnight in an ammonium bicarbonate/tris(2carboxylethyl) phosphine solution at 37 1C. An initial 2 ml/min fraction was injected for MS/MS Q-TOF analysis to determine sample preparation's peptide concentration and quality. Final data was collected from a 180 min analysis for each sample. Analysis of equal concentrations of peptide injections per experimental group were made using the Mascot database software (Matrix Science Inc., Boston, MA, USA), which provided a list of proteins, that matched the peptides amino acid signatures identified during the ms/ms analysis. Identified proteins were compared for each experimental group.
Wound healing
A 'scratch' was made in the cell monolayer with a sterile 20 mm pipette tip. Images were recorded (three per well) at Â 10 magnification using Nikon Eclipse TE 2000-U (Nikon Instruments Inc., Melville, NY, USA). This was considered as T 0 . Following incubation for 10 h at 37 1C, the wells were imaged again at the same places where captured at T 0 . The experiment was conducted in duplicate and cell motility was expressed as (T 0 ÀT 10 )/T 0 which represents the rate of movement over 10 h.
Transwell migration
Cells suspended in serum free media were added to gelatin (6 ng/ ml)-coated sterile 8 mm pore inserts. The lower chambers of the wells were filled with 10%FBS containing media and incubated at 37 1C for 5 h. The interior of the insert/filters was carefully cleaned and the filters stained with crystal violet. Eight random frames of each insert were photographed using Nikon Eclipse TE 2000-U (Nikon Instruments Inc.) and the stained cells in each frame were enumerated. Each experimental group was assayed in triplicate.
Transwell invasion
Cell suspension in serum free media was added into sterile 8 mm pore Matrigel-coated filters (BD, Fraklin Lakes NJ, USA). The inserts were lowered into 24-well plates containing 10 mg/ml fibronectin containing media and incubated at 37 1C for 18 h. Staining and result recording was performed in the same way as the migration assay described above.
Endothelial cell migration and invasion assays were done in the same manner as described above with a few changes. Primary rat lung derived microvascular endothelial cells (USA Center For Lung Biology Core, Mobile, AL, USA) were seeded into the upper chambers previously hydrated inserts and migration/invasion was recorded in response to CM from each experimental group or recombinant SHH (R&D Systems, Minneapolis, MN, USA) or 100 ng/ml VEGF (R&D Systems). All experimental groups were assayed in triplicate.
Cell proliferation
Cells were plated in triplicate in 24-well tissue culture plates. Each day cells were detached and counted using a hemocytometer. The assay duration was 7 days. Counting for each cell type was done for each day in triplicate.
Anchorage independent growth (soft agar colony formation) Cells (4000) from each experimental group were mixed in a 1:1 ratio with 0.7% agar in DMEM/F12 supplemented with 10% serum and layered on to a bed of 1.5% agar in serum free media. The agar was kept hydrated with fresh growth medium. The assay was terminated after 4 weeks and colonies with X50 cells were counted under a microscope. Colonies were also stained using 1:100 diluted crystal violet and recounted. Each experimental group was assayed in triplicate.
Foci formation
Five hundred cells were disseminated in triplicate in 10 mm cell culture plates. At the end of 3 weeks foci were fixed using methanol, stained using crystal violet and counted.
Endothelial cell network formation
Microvascular endothelial cell suspension in CM from test groups was added to wells containing Growth Factor Reduced Matrigel (BD). After 6 h network formations were counted using the Nikon Elements image analysis software (Nikon Instruments Inc.). Network lengths were measured from branch point to the next adjacent branch-point within the network structures (Arnaoutova and Kleinman, 2010) .
Luciferase assay
Cells were transfected with reporter and effector constructs as follows: tumor cells were co-transfected with pLNCX or pLNCX-GLI and pGL3-8xGLI (gifted by Dr Philip Beachy, Stanford University, CA, USA; the Â 8 Gli fragment was subcloned into pGL3 promoter vector) or pGL3-CYR61 promoter to assess GLI binding, Hh signaling activation and CYR61 regulation, respectively. 33-40 h post-transfection cells were lysed overnight and assessed for luciferase activity. Data is normalized to total protein concentration. Each assay was done in triplicate and reproduced three times.
The GLI-binding site in the promoter of CYR61 was mutated (pGL3-GLI/M-CYR61) or deleted (pGL3-GLI/ D-CYR61) by inside-out PCR with the following primers: GLI/M-forward: 5 0 -GCGGCCGCCCACCCAG-3 0 /reverse: 5 0 -CTGAGAGGGAGGAACAAAAG-3 0 , GLI/D-forward: 5 0 -CCACCCAGTCCAGGCA-3 0 /reverse: 5 0 -CTGAGAGGG AGGAACAAAAG-3 0 .
Chromatin immunoprecipitation assay MDA-MB-231-pIRES2-EGFP (control) and MDA-MB-231-pIRES2-SHH were processed for immunoprecipitation using the ChIP-IT Express Enzymatic kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer's protocol and recommendations. GLI1(C-18; sc-6152x; Santa Cruz) and normal rabbit IgG were used for immunoprecipitation. Primers targeting the putative GLI1 binding region in the promoter of CYR61 (forward: 5 0 -CGGTCAACTCGCATCA CC-3 0 and reverse: 5 0 -CGACTTATGTTGGGAAGGG-3 0 ) amplified a 165 base pair product from sheared immunoprecipitated chromatin template. Non-targeting primers (forward: 5 0 -GCCCTGCGACCACACCAA-3 0 and reverse: 5 0 -CGTAT GCGCTTTCGTTGGG-3 0 ) were also used as a negative control for primer specificity. PCR products were visualized on a 2.5% agarose gel.
Animal experiments
Experiments were conducted under protocol approved by the Institutional Animal Care and Use Committee of the University of South Alabama, Mobile. Cells (200 000) were injected into the mammary fat pad of female 6 week old athymic nude mice, as previously described (Shevde et al., 2006; Das et al., 2009) . Mice were monitored biweekly for tumor development. Tumors were excised by survival surgery when they attained a mean tumor diameter of 10 mm. Ten weeks post tumor excision mice were euthanized and assessed for pulmonary metastasis. Pulmonary metastases were assessed by (1) GFP-expressing tumor cells in the lungs detected under UV-FITC, (2) staining with Bouin's reagent and (3) recovery of GFP-expressing tumor cells from the lungs in cell culture.
Isolation of metastatic breast cancer cells from mice lungs.
Lungs harvested from mice were homogenized to recover a cell suspension that was resuspended in fresh cell culture media supplemented with appropriate selection antibiotics. Cells were incubated and grown according to cell culture methods described above.
Immunohistochemistry
Xenografted mice tissues were fixed in 10% formalin and embedded into paraffin. Sections (4 mm) were processed for immunohistochemistry. Excised tumor tissues were examined for SHH, Ki67 (cell proliferation), Griffonia (Bandeiraea) Simplicifolia Lectin I isolectin B4 (Vector Laboratories, Burlingame, CA, USA) (endothelial cell surface marker/angiogenesis) (Singh et al., 2009) and CYR61 diluted in Antibody Diluent from BD Pharmingen. Deparaffinized sections were subject to antigen retrieval in citrate buffer (Antigen Unmasking Solution, Vector Laboratories) in a decloaking chamber (Biocare Medical, Concord, CA, USA) at 125 1C for 30 s. Tissue sections were probed with primary antibodies: anti-SHH (1:50 Millipore, Temecula, CA, USA), anti-Lectin (1:25, Vector Laboratories, Inc.,), anti-CYR61 (1:300, Santa Cruz) followed by appropriate secondary antibodies and using the DAB peroxidase solution (Vector Laboratories). The staining intensity was represented as an immunoreactive score (Metge et al., 2008) . Microvessel density was quantitated directly by counting the number of positive vessels that were stained.
Statistical analysis
Statistical analyses between experimental groups were assessed using GraphPad Prism 4 (GraphPad Software, Inc., La Jolla, CA, USA). Student's t-test, Mann-Whitney, one-way ANOVA or two-way ANOVA were applied based on the statistical mandates or suggestions of each analysis.
Abbreviations CYR61, cysteine-rich angiogenic inducer 61; Hh, hedgehog pathway; MVD, microvessel density; SHH, Sonic hedgehog ligand.
